Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 15/20 | 0.63 |
| ▸ | SCN1A | P35498 | 2/20 | 0.40 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 5/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26462867 | 0.84 | SCN5A (0.57) | SCN5ASCN1ASCN2A | |
| SCHEMBL26460440 | 0.84 | SCN5A (0.64) | SCN5ASCN1ASCN2ASCN10AKCNH2 | |
| SCHEMBL26460459 | 0.82 | SCN5A (0.56) | SCN5ASCN1ASCN2ASCN10AKCNH2 | |
| SCHEMBL26462424 | 0.82 | SCN5A (0.56) | SCN5ASCN1ASCN2ASCN10AKCNH2 | |
| SCHEMBL26461696 | 0.81 | SCN5A (0.60) | SCN5ASCN1ASCN2ASCN10AKCNH2 | |
| SCHEMBL26462859 | 0.81 | SCN5A (0.67) | SCN5ASCN1ASCN2ASCN10AKCNH2 | |
| SCHEMBL26462399 | 0.79 | SCN5A (0.64) | SCN5ASCN1ASCN2A | |
| SCHEMBL26460261 | 0.78 | SCN5A (0.60) | SCN5ASCN1ASCN2ASCN10A | |
| SCHEMBL935897 | 0.78 | SCN5A (1.00) | SCN5ASCN1ASCN2ACYP1A2 | |
| SCHEMBL26460412 | 0.76 | SCN5A (0.61) | SCN5ASCN1ASCN2ASCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230134428-A1 | FUSED HETEROARYL COMPOUNDS, AND METHODS THEREOF FOR TREATING DISEASES, DISORDERS, AND CONDITIONS RELATING TO ABERRANT FUNCTION OF A SODIUM CHANNEL | PRAXIS PRECISION MEDICINES, INC. | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230134428-A1 | FUSED HETEROARYL COMPOUNDS, AND METHODS THEREOF FOR TREATING DISEASES, DISORDERS, AND CONDITIONS RELATING TO ABERRANT FUNCTION OF A SODIUM CHANNEL | SCN1A, SCN3A, SCN2A | SCN5A 7/4885SCN1A 1/4885SCN2A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.